The Impact of Biosimilar Competition. Five Observations by IMS Health

12

Febbraio 2016

The report presents a set of Key Performance Indicators (KPIs) for European countries. In this document IMS Health suggests five key observations based on the data

IMS Health has produced the report The Impact of Biosimilar Competition (based on 2014 figures) for the European Commission. The report has been published in December 2015. Input to the report was given by the European Generic medicines Association, the European Federation of Pharmaceutical Industries and Associations and and EuropaBio, the European Association of Bio-Industries. The report presents a set of Key Performance Indicators (KPIs) for European countries. In this document IMS Health suggests five key observations based on the data.

Documenti collegati:

IMS_Observations_Impact_of_Biosimilar_Competition_2015.pdf

Sede legale: Via Molise, 16 – 73100 Lecce (LE)
Sede operativa : Via Miglietta, 5 c/o Asl Lecce (Ex Opis) – 73100 Lecce (LE)
Tel/Fax 0832 520165 - Email: info@apmarr.it - PEC: apmarr@legalmail.it
C.F.: 93059010756 - P.Iva: 04433470756 - Codice SDI: W7YVJK9
Privacy Policy